Skip to main content
Genxone Spolka Akcyjna logo

Genxone Spolka Akcyjna — Investor Relations & Filings

Ticker · GX1 ISIN · PLGENXN00013 LEI · 25940043REFNZY18T558 WAR Professional, scientific and technical activities
Open in API
Filings indexed 145 across all filing types
Latest filing 2026-04-13 Regulatory Filings
Country PL Poland
Listing WAR GX1

About Genxone Spolka Akcyjna

http://www.genxone.eu

Genxone is a biotechnology company that develops products and solutions based on advanced nucleic acid technologies. The company specializes in Next Generation Sequencing (NGS) and medical diagnostics, offering a range of DNA and RNA sequencing services. It is a pioneer in the application of nanopore sequencing technology, developed by Oxford Nanopore Technologies, being one of the first laboratories globally to utilize it for commercial applications in science, business, and medicine. Key services include whole-genome sequencing, metagenomic sequencing, 16S/ITS gene sequencing, custom-designed analyses, and comprehensive bioinformatic support.

Recent filings

Filing Released Lang Actions
Informacja o wyborze najkorzystniejszej oferty - Content (PL)
Regulatory Filings Classification · 1% confidence The text is a management board notification that the company’s bid was selected in a procurement process by a university. It is a standalone regulatory announcement of a contract award—not an earnings release, financial report, or presentation and does not fit any specific category such as M&A, financing, share transaction, or dividend. It is therefore best classified under the general “Regulatory Filings” fallback category (RNS).
2026-04-13 Polish
Aktualizacja informacji dotyczących istotnej umowy - Content (PL)
Capital/Financing Update Classification · 1% confidence The document is a short corporate announcement informing investors on the signing of an annex to a payment agreement and detailing the revised repayment schedule and debt forgiveness. It is not a full financial report or management discussion, but rather a specific financing arrangement update. This aligns with the Capital/Financing Update category (CAP).
2026-03-25 Polish
Informacja o podpisaniu umowy - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement regarding the signing of a specific commercial contract between genXone S.A. and the National Institute of Geriatrics, Rheumatology and Rehabilitation. It details the subject of the contract, the timeline, and the financial value. Since it does not fit into specific categories like M&A (TAR), financial reports (10-K/IR), or dividend notices, and is a standard regulatory disclosure of a material event, it falls under the general regulatory filing category.
2026-03-18 Polish
Informacja o wyborze najkorzystniejszej oferty - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a short announcement from the company (genXone S.A.) regarding the selection of their offer in a public procurement process. It describes a specific business development (winning a contract) rather than a financial report, proxy, or governance document. Since it is a standard regulatory announcement regarding company operations that does not fit into specific categories like M&A or share issues, it falls under the general regulatory filing category.
2026-02-17 Polish
Podpisanie umowy warunkowej o istotnym znaczeniu - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is very short (1066 characters) and describes a specific business event: the receipt of a conditional agreement (umowa warunkowa) for sequencing services worth 4,284,410.00 PLN. This is a material event disclosure, likely related to a significant contract or transaction. It is not an Annual Report (10-K), Earnings Release (ER), or a formal presentation (IP). Since it details a significant contract award/agreement, it falls under general corporate activity disclosure. Given the options, this type of specific, material contract announcement that doesn't fit neatly into financing (CAP), M&A (TAR), or insider trading (DIRS) is best classified as a general Regulatory Filing (RNS), which serves as a catch-all for significant, non-standard disclosures in many jurisdictions, especially when the text is a direct regulatory update (indicated by 'W nawiązaniu do raportu ESPI'). It is not an announcement *about* a report, but the report itself (a disclosure).
2024-03-08 Polish
Informacja o wyborze najkorzystniejszej oferty - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ('Zarząd') of a Polish company ('Emitent') regarding the selection of its offer as the most advantageous in a tender process for sequencing services. It details the contract value (4,284,410.00 PLN) and the timeline, mentioning that the final contract is pending ('oczekuje na zawarcie umowy warunkowej'). This type of announcement, concerning a significant business contract award, is typically classified as a material event disclosure. Since it is not a standard financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it relates to a significant business development, it fits best under the general category for regulatory announcements that do not fit elsewhere, which is Regulatory Filings (RNS). It is not a Director's Dealing (DIRS), Capital Change (CAP), or M&A (TAR). Given the context of Polish regulatory filings (ESPI reports mentioned), RNS is the most appropriate general classification for material, non-standard disclosures.
2024-03-06 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.